Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.
Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.
Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.
The company's product pipeline includes two promising therapies:
- SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
- SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.
Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.
The Global Small Interfering RNA (SiRNA) Market is projected to reach $964.17 Million by 2030, with a CAGR of 8.6% from 2023 to 2030. Key insights show that liposome-based systemic therapy represents 52.01% of the market share. The cancer segment leads therapeutics with a 38.14% share, while research institutions account for 43.07% of applications. North America dominated the market in 2022 due to robust R&D activities. Significant partnerships, such as Silence Therapeutics with Hansoh Pharmaceutical, are accelerating market growth in the APAC region. The report emphasizes a focus on RNA functions and its therapeutic potential for various genetic disorders.
Silence Therapeutics plc, trading on Nasdaq under the symbol SLN, will have its President and CEO, Craig Tooman, present at the virtual SVB Securities Global Biopharma Conference on February 15 at 3:00 p.m. ET. The presentation will be accessible via the Investors section of the company’s website. Silence is focused on innovating precision medicines through RNA interference technology, targeting diseases with significant unmet needs. Key product candidates include SLN360 for cardiovascular risk and SLN124 for hematological diseases, complemented by collaborations with notable partners like AstraZeneca.
Silence Therapeutics plc, trading under Nasdaq: SLN, has appointed J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff. Gabriel brings over 25 years of experience in supply chain and manufacturing, crucial for advancing the company's clinical pipeline. Silence focuses on RNA interference technology to target genetic diseases and has product candidates like SLN360 and SLN124. The company also collaborates with AstraZeneca and other firms to enhance its research initiatives.
Silence Therapeutics plc (NASDAQ: SLN) presented key updates on its SLN360 and SLN124 programs at the 41st Annual J.P. Morgan Healthcare Conference. The SLN360 phase 2 study for high-risk atherosclerotic cardiovascular disease has begun dosing, with enrollment completion expected by Q4 2023. Preliminary data from the phase 1 study indicate significant reductions in lipoprotein(a) levels. Additionally, the SLN124 phase 1/2 study for polycythemia vera is now enrolling participants, with data from thalassemia patients expected in Q4 2023. Silence anticipates a pivotal year ahead.
Silence Therapeutics, trading under the ticker SLN, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 12 at 9:45 a.m. PT. The presentation by Craig Tooman, CEO, highlights the company's commitment to innovative biotechnology solutions aimed at silencing diseases through RNA interference. A live webcast will be available on the Silence Therapeutics website, with an archived replay to follow after the event.
Silence is focusing on RNAi-based medicines and has ongoing collaborations with leading pharmaceutical companies.
Silence Therapeutics plc (Nasdaq: SLN) reported its Q3 2022 financial results, showcasing a net loss of £7.1 million, an improvement from £9.9 million in Q3 2021. Revenue rose to £3.4 million, driven by collaboration agreements. Key milestones include anticipated phase 2 studies for SLN360 and SLN124, with SLN124 receiving FDA Fast Track Designation. The company's cash position stood at £90.0 million following a successful offering raising $56.5 million in August. This reinforces the company’s commitment to advancing its innovative pipeline.
Silence Therapeutics plc (NASDAQ: SLN) announced that CEO Craig Tooman will present a business overview at the Jefferies London Healthcare Conference on Wednesday, November 16, at 8:00 a.m. GMT. The conference aims to highlight Silence's innovative RNA interference technology, which targets gene silencing to tackle diseases with significant unmet needs. The live presentation will be available via webcast on Silence's website, with an archived replay accessible after the event.
Silence Therapeutics has presented promising data from its APOLLO phase 1 study of SLN360, targeting elevated lipoprotein(a) (Lp(a)), a significant cardiovascular risk factor. Results showed that participants receiving 300 mg and 600 mg doses maintained median reductions in Lp(a) levels exceeding 80% over five months. Some maintained reductions of up to 50% of baseline at one year. No new safety concerns arose, suggesting SLN360's potential for infrequent dosing. The company plans to advance into a phase 2 study for patients with atherosclerosis in late 2022.
Silence Therapeutics plc, a leader in siRNA therapeutics, announced preliminary results from the GEMINI II phase 1 study of SLN124 targeting the TMPRSS6 gene in adults with non-transfusion dependent thalassemia. The study showed an encouraging safety profile with no serious adverse events or dose limiting toxicities. Pharmacokinetic and pharmacodynamic evaluations are ongoing, with results expected next year. SLN124 has received FDA Fast Track Designation for polycythemia vera, and a phase 1/2 trial is planned for later this year, showcasing its potential across various hematological conditions.
Silence Therapeutics plc (Nasdaq: SLN) announced that Giles Campion, MD, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 4 at 3:45 p.m. ET in New York. The event can be viewed live on the company's website. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet medical needs, leveraging its mRNAi GOLD™ platform. Major products include SLN360 for cardiovascular risk and SLN124 for rare hematological diseases. Collaborations with AstraZeneca and others enhance their research efforts.
FAQ
What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?
What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?
What is Silence Therapeutics Plc?
What is RNA interference (RNAi)?
What is SLN360 therapy?
What is SLN124 therapy?
How does Silence Therapeutics target specific cells?
What diseases are Silence Therapeutics' therapies targeting?
How does SLN360 reduce cardiovascular risks?
What is the role of hepcidin in SLN124 therapy?
Where can I find more information about Silence Therapeutics' projects?
What makes Silence Therapeutics unique?
